key: cord-0793949-avn4jn3w authors: Akter, Fariya; Araf, Yusha; Naser, Iftekhar Bin; Promon, Salman Khan title: Prospect of 3D Bioprinting over Cardiac Cell Therapy and Conventional Tissue Engineering in the Treatment of COVID-19 Patients with Myocardial Injury date: 2021-09-30 journal: Regen Ther DOI: 10.1016/j.reth.2021.09.007 sha: 13e162ea6b6d381872b4ad11425ffb3fa1029388 doc_id: 793949 cord_uid: avn4jn3w Due to multiple mutations of SARS-CoV-2, the mystery of defeating the virus is still unknown. Cardiovascular complications are one of the most concerning effects of COVID-19 recently, originating from direct and indirect mechanisms. These complications are associated with long-term Cardio-vascular diseases and can induce sudden cardiac death in both infected and recovered COVID-19 patients. The purpose of this research is to do a competitive analysis between conventional techniques with the upgraded alternative 3D bioprinting to replace the damaged portion of the myocardium. Additionally, this study focuses on the potential of 3D bioprinting to be a novel alternative. Finally, current challenges and future perspective of 3D bioprinting technique is briefly discussed. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which gives rise to is the reason behind the current global health emergency. According to WHO, 169,597,415 people are infected, including 3,503,582 deaths, as of 30 th May 2021 since its origin in December 2019 [1]. Though it is considered that SARC-CoV-2 affects the respiratory system, direct and indirect involvement of the cardiovascular system has been identified in various studies [2] [3] [4] [5] [6] , and the associated complications are closely related to worse prognosis and mortality [7] . In addition to that, medications used to treat COVID-19 are responsible for indirect cardiovascular complications and adverse side effects [8] [9] [10] [11] . COVID-19 drugs initiate different cardiovascular problems like bundle branch block, AV block, ventricular arrhythmia, cardiomyopathy, myocardial injury, hypertension, along so many other long-term complications [12] [13] [14] [15] [16] [17] . Though conventional techniques like, Cardiac cell therapy and myocardial tissue engineering are capable of producing new tissues, studies show various limitations of these techniques that make these techniques impractical to use [18, 19] . In search of an appropriate and better alternative, we find 3D bioprinting one of the modern biotechnological developments which can deposit biomaterials and bioactive cells onto a computer-aided predetermined design in a layer by layer manner to print the construct [20] . Moreover, this technique can produce a highly continuous and stable biological pattern of the native heart with high-resolution stimulation that facilitates finding ways of myocardial tissue repair and regeneration [21, 22] . 3D bioprinting is the technique for regenerating an utterly new tissue or organ implanted into the host. Back in 2019, the world's first patient-specific vascularized renal dysfunction, electrolyte disturbances, and patients on ventilators and vasopressors [67] . The interaction between SARS-CoV-2 and the RASS system causes electrolyte imbalance, increasing the risk of arrhythmias [68] . Electrophysiologic evidence shows that right ventricular arrhythmias can be caused by COVID-19, related to mortality [69] . Guo et al. showed the relationship between ventricular tachycardia or ventricular fibrillation with/without myocardial injury. Patients with myocardial injury had a higher rate of getting ventricular tachycardia or ventricular fibrillation, and this study suggests the interlink of arrhythmia and cardiovascular system in COVID-19 patients [31] . COVID-19 can cause both arterial and venous thrombosis [70] . COVID-19 infected induvial has a higher chance of having venous thrombosis [71] . Clotting and development of coagulopathy is a deadly combination for severe and critical COVID-19 patients. A study including 184 patients showed that around 27% of patients had VTE, and 3.7% had arterial thrombotic events with the help of CT angiography and ultrasound [72] . Most of the studies use the amount of D-dimer as a reference for VTE. In the study of Zhou et al., 81% of COVID-19 patients died with elevated D-dimers (>1g/L) [26] . Introduction of the virus into myocardial cells can induce the release of inflammatory molecules like TNF-α, IL-1β, IL-6, IL-10, virus-specific T lymphocytes, monocytes MMPSs, NK cells, macrophages, etc., together cause systemic hyperinflammation. (3). Infection in the respiratory tract induces the imbalance between oxygen demand and supply known as Type 2 Myocardial Infarction or hypoxia. Thus, indirectly damage the myocardium. (4). Medications used to treat COVID-19 are also responsible for indirect myocardial injury as they cause complications like QTc prolongation, AV block, arrhythmias, heart failure, hypertension, etc. The medicines used to treat COVID-19 are also be responsible for myocardial injury. For instance, to prevent the entry of SARS-CoV-2 through ACE2, ACEIs and ARBs are being used [43] like chloroquine and hydroxychloroquine. Though these medicines inhibit viral entry and decrease the chance of sudden cardiac death, they cause QTc prolongation, bundle branch block, AV block, ventricular arrhythmias [47] , cardiomyopathy [10] , and direct myocardial toxicity [73] . Various monoclonal IL-6 receptor inhibitors like tocilizumab and siltuximab, anti-interferon-gamma antibodies -Emapalumab, azithromycin, and corticosteroids-were examined ensure the efficiency and have proven their efficacy already [74] . Though tocilizumab inhibits IL-6 and cytokine storm, it causes a type of rare hypertension [47] , hypercholesterolemia [73] . Moreover, it is responsible for decreasing hepatic LDL receptor expression and increasing serum LDL cholesterol [75] , which can cause atherosclerotic cardiovascular disease. Studies found that exogenous cell transplantation into damaged myocardium can improve myocardial function and vascular supply [76] . Transplanting cells to the damaged region for cardiac repair is known as cardiac cell therapy [77] . In situ cellular cardiomyoplasty, cells are being injected directly or intravenously into the infarct [78] . Various types of cells including, fetal cardiomyocytes, neonatal cardiomyocytes, autologous skeletal myoblasts, bone marrow stem cells, embryonic stem cells, adipose-derived mesenchymal stem cells, induced pluripotent stem J o u r n a l P r e -p r o o f cells, have been used for this purpose. Reports claim that the mammalian heart has intrinsic regenerative potential, and cardiac stem cells (CSCs) can differentiate into cardiomyocytes after in-vitro stimulation with oxytocin. Moreover, CSCs assist myocardial regeneration in infarcted hearts of rat models. Besides all the cell sources, a novel alternative cell source is induced pluripotent stem cells (iPSCs), which can be obtained by treating differentiated adult cells with four genes s (Oct3/4, Sox2, c-Myc, and Kfl4) [79] or (OCT4, SOX2, NANOG, and LIN28) [77] . Tissue engineering (TE) approaches for cardiac damages have been studied recently. As myocardial tissue lacks regenerative capability, TE can be a potential alternative for restoring the functionality of damaged myocardial tissue [18] . There are three fundamental elements for a successful TE; cells, extracellular matrix, biomimetic signal, and bioreactors [80] . The primary approach is to seed cells capable of forming cardiomyocytes onto a scaffold in vitro and introducing the construct in the infarcted region [78] . Though various advancements have been introduced in the treatments of injured myocardium, the adult heart cannot regenerate effective cardiomyocytes after being injured or infracted [81] , leading to regional contractile dysfunction [18] . If the injured area is large, it can degenerate the remaining myocardium and lead to congestive heart failure [18] . Various reports show the longlasting cardiovascular effect of COVID-19 on the heart, which indicates that the injured area is enormous and can cause sudden death to the recovered COVID-19 patients. Collecting the correct number of cells for transplantation is a challenge. Fetal cardiomyocytes were capable of limiting scar expansion and heart failure in rat models. Thus, researchers started working with it and found out the benefits. However, using fetal cardiomyocytes in humans is not feasible as acquiring enough human fetal tissue is challenging [18, 82] tissue in porcine has also been observed. Immunogenicity and risk of myocardial complications are associated with most of the cells used in the process [83] . Evidence has been collected from animal models and clinical trials that different cell sources can cause various side effects in patients after being treated with Cardiac cell therapy. The utilization of embryonic stem cells for cell therapy can increase the chance of tumorigenesis [84, 85] , stem cell metastasis [86] , immunogenicity [87] . Skeletal myoblasts can create adverse effects like arrhythmogenesis [88, 89] . Another challenge of cardiac cell therapy is determining the amount of injury in a patient. There is a difference in the benchmark for reproducible engraftment of large numbers of cells based on myocardial damage. The engraftment for early post-myocardial infarction patients is different from the patient with end-stage cardiac dysfunction [90] . Increased risk of arrhythmias even after feasible myoblast transplantation is one of the significant concerns of cardiac cell therapy [91] . If the transplantation is successful, the transplanted cells must transdifferentiate into cardiomyocytes and survive for a long time to serve the need. However, the infarcted region and the surroundings do not help the cells survive in the optimal environment [18] , making the process inefficient. A significant disadvantage of tissue-engineered products is the destructive host response. After introducing these engineered constructs into the human body, they induce an innate immune response known as foreign body response along with an adaptive immune response if it contains an immunologic biological component. Chronic inflammation can also be initiate after implantation of the engineered construct. With the combination of all these features, a high chance of graft rejection initiates after the introduction [92] . in tissue engineering. The study clearly shows the number of disadvantages is more than the advantages, which include the toxic effect of biomaterial scaffolds, inflammation risk, the chance of poor vascularization if more than 3-sheets are being used, the requirement of lifelong treatment with anticoagulants, and many more which indicates the ineffectiveness of the biomaterials. Additionally, they pointed that materials without having all the required characteristics can induce a non-functioning heart associated with various complications [93] . Myocardial tissue-engineered constructs use multiple defined and undefined cells which support tissue formation, vascularization, secrete signaling molecules for cardiomyocyte survival, proliferation and maturation. However, long-term survival of the myocardial grafts cannot be possible as sufficient nutrient supply is crucial in in-vivo conditions [94] . Fabrication of aligned and thick cardiovascular tissue is very hard as all the cells need to have a microvascular network for exchanging nutrients and oxygen [95] . Though several tissue engineering technologies have created cardiac patches with large surface areas, vascularization remains a significant challenge that affects oxygen supply in cells both in vitro and in vivo [96] . feature of vascularization that needs to be modified is unclear, making the procedure even more complicated [96] . According to Wang et al., other limitations of tissue engineering are the inconsistence of stiffness between the engineered tissue construct and the myocardium, which can be responsible for implanting a dysfunctional construct with poor engraftment inside the human body [77] . Engineering large cardiac constructs through tissue engineering are challenging as cardiac tissues are composed of ECM proteins and different cells with different alignments to make spontaneous contraction possible. All the properties of the native myocardium cannot be maintained throughout. As a result, the construct cannot contract like the native one, and the cells died after a few times [95] . Though different organs can be made by 3D scaffold-based tissue engineering, successful results are only observed for avascular organs. Developing a highly vascularized organ like the heart is challenging to fabricate to be functional for a more extended period because of the massive number of branched blood arteries and capillaries [95] . Moreover, seeding cells on these scaffolds lead to cell death and can cause poor cellular performance [106] . A perfect bio-ink should be selected for the fabrication to make a 3D structure that mimics the actual organ/tissue. To achieve the ideal bioink, the mixture of different biomaterials based on the mechanical properties acquire attention [106] . The perfect 3D structure, along with required functions, can be achieved with the help of printable biomaterials (bioinks), 3D bioprinters of different techniques, and microenvironmental regulations for promoting tissue morphogenesis. The whole Bioprinting procedure can be divided into three distinct stages. The first one is the preprocessing stage, where all the planning for successful bioprinting is present. Imaging is a must to analyze the overall structure, which will help make the blueprint for bioprinting. The second phase is Bioprinting. All the complexity is present in this stage. Choosing the right bioprinting technology and the appropriate bioink and cell is tricky as all these things can manipulate the effectiveness of the printed 3D construct. Moreover, the bio-ink preparation is a bit technical as it requires a suitable cell source, the perfect scaffold materials, and the additives like growth factors, chemicals, microcarriers, etc. [74] . Cell viability is one of the most influencing factors that can help to get a preferable result out of the 3D bioprinted construct. Cell viability depends on factors such as the duration of the whole printing procedure, the sensitivity of the cells, etc. Selecting the appropriate bioprinting technique that requires less time to complete the whole procedure along with supplying all the required components to the cells (culture media) will be helpful enough to secure the required number of cells [112] . Finally, the third stage is the post-bioprinting stage, and it includes all the steps that need to be done to get a mature and fully functional bioprinted construct for in-vivo usage [74] . To evaluate the quality of the bio-printed construct various in vitro analyses can be done. Assessment of cardiac biomarkers, efficient contractile force (ECF), spontaneous action potential (SAP), and overall calcium regulation (OCR) will be of great help. Estimation of J o u r n a l P r e -p r o o f the muscle construction, depolarization-repolarization action potentials of the newly bioprinted construct will determine the quality. Additionally, transplantation of the construct into the infected hearts of immune-deficient rats can deduce the orthotopic safety and effectiveness of the 3D bioprinted construct [20] . The transplanted construct helped reduce the infarction area, increased neovascularization, and enhanced the ejection fraction and cardiac output, thus showing a remarkable therapeutic effect [20] . Several in vivo studies have already evaluated the performance of the 3D bioprinted construct to treat myocardial infarction. 3D bioprinted prevascularized and functional constructs stimulated strong vascularization, tissue matrix formation after implanting into rat hearts which is a positive indication for utilizing personalized 3D bioprinted construct to Factors such as, age, preexisting cardiovascular diseases, cerebrovascular diseases, diabetes mellitus, chronic obstructive pulmonary disease, ARDS, higher creatinine level of COVID-19 patients increase the risk of greater cardiovascular damage that eventually lead to death [7] . The ratio of myocardial damage can determine whether the heart will regain its competence or not. A highly injured myocardium can also cause sudden cardiac death or long-lasting cardiovascular complications [18] . Tissue engineering of the larger damaged area of the myocardium is difficult because of its complex nature [109] . 3D bioprinted heart will be the most efficient solution o prevent long-lasting cardiovascular complications or sudden cardiac death, as it is capable of mimicking the complex structure of the myocardium [107] . To ascertain the therapeutic potential of the 3D bioprinted construct, 3D bioprinted constructs have been transplanted in mouse MI model, and the outcomes have been analyzed. Surprisingly, a cardiac function has been improved with the help of the transplanted cells as they influenced tissue remodeling. Besides vascularization and prolonged cell survival have been evident that indicates the capillary network formation for nutrient and oxygen supply into the cells [110] . Compared to conventional tissue engineering techniques, 3D bioprinting can influence the stem cells to differentiate during various stages of the whole procedure. This influence of differentiation can vary based on the choice of stem cells, bioprinting method, selection of scaffold, additives, and mechanical forces. Moreover, these stem cells have immunotolerance and can expand after being incorporated into the target tissue. To promote differentiation, even more, microcarriers can be a source of great help. These small polymer spheres can influence the differentiation after being added to the bioink and can solidify the scaffold. This differentiation influence is significant for the overall potential of the 3D bioprinting process, which makes the technique better than the rest [74] . The 3D bioprinting process utilizes two types of photo cross-linkable hydrogels: rigid works for the root, and soft, which works for the leaflets. The printing procedure was extrusion-based, and within 45 minutes, the heart was printed, indicating that 3D bioprinting is a speedy technique compared to any other method for myocardial regeneration [108] . Generally, the other regeneration techniques emphasize more on the shaping capability of the ink. On the other hand, the 3D bioprinting technique focuses on producing high biocompatibility and biodegradability of the bio link to help merge the living cells or bioactive molecules. The use of hydrogel dECM has excellent potential in 3D CTE bioink preparation. Cardiac dECM is capable of reproducing the same physical and mechanical microenvironment along with therapeutic potential. Proteomic research of the physiological and pathological dECM of the cardiological system will be helpful to extricate more functional factors which support the production of advanced 3D CTE bioink [20] . Another advancement of 3D bioprinting that makes this technique a better alternative is the highfidelity replicating of supple and tough textures de novo. For example, the printing of many functional skeletal muscles. This has been possible by the precise control of the composition, structure, and shape before producing the construct [20] . 3D bioprinting can develop heterogeneous 3D scaffolds of muscular mechanical strength that pose all the required characteristics, morphology, and accuracy of the native myocardium. All of these are possible with the help of a computer-aided design (AutoCAD) facility to make a biomimetic 3D scaffold of the native heart shape [109] . Moreover, this process has precise control over various compositions, structural complexity, distribution, effective printing of all the tissues with accurate features [110] . 3D bioprinting is a promising approach to generate porous inner structure, which helps to provide the required nutrients and oxygen to other tissues [111] . As the technique is automated, mass production of cells is more accessible, and the construct will be of high resolution [106] . Additionally, the 3D products contain precise architecture which is reproducible and repeatable [112] . Vascularization in the 3D printed myocardial cell construct is another outstanding advancement. Carbohydrate filaments were utilized to construct a 3D printed vascular network that can be perfused with pulsatile and high-pressure flows [113] . In another research, micropores have been used to ensure perfusion, and thereby all the metabolic processes have been maintained in 3D engineered hepatocyte tissue [114] . As a noninvasive spatial micropatterning technique, ultrasound standing wavefields are employed, directing endothelial cells to form vascular networks in the engineered tissues by controlling sound in the sound field [115] [116] [117] [118] . To stimulate muscle This technique uses tissue-specific models for bioprinting the organ or specific tissues, which are helpful to test therapeutic schemes and aid in the clinical diagnosis and treatment of disease through the replacement of the injured tissues. Selection of appropriate drugs regenerative medicine can be created with a lesser amount than conventional tissue engineering. Personalized pathophysiological conditions can be determined beforehand from the genome, proteins, and medical/family history, which will help reduce life-threatening effects [111] . As the 3D bioprinting technique can regenerate customized and complex 3D models of human tissues and organs, it is beneficial to reduce animal testing. It can overcome all the ethical concerns related to animal testing [20] . Scaffolds of the engineered construct can create problems like immune reaction and degradability, which can be life-threatening. That is why the scaffold-free 3D bioprinting technique has emerged as an alternative. Here the cells are being spread in a 3D environment, and the rapid differentiation creates a solid mass by cell-cell adhesion. After the complete regeneration, the cells are being placed layer by layer with 3D printer support and develop a tissue-like structure robotically [109] . Despite numerous advancements in 3D bioprinting, this field is not in its highest developed form yet [119] . Cardiovascular constructs like the vascular constructs, myocardium, heart valves, tissues, etc., have already been printed successfully with distinct structures and functions [110] . However, to make 3D bioprinting successful, one challenge is selecting and preparing the perfect bioink. The bioink must pose all the essential characteristics, and it must be maintained in-vivo for a more extended period. Research is going on to develop a bioink of balanced bio printability and bio-functionality [106] . As the bioprinting technique needs bioactive polymers for the procedure, the selected molecules are sometimes biologically so active that they can cause unwanted cellular interactions and unfavorable stem cell differentiation. Thus, choosing the appropriate biomolecule J o u r n a l P r e -p r o o f can be a challenge [74] . Another challenge can be the selection of fabrication strategy as the complex organs contain cells of different patterns. Thus, the printing may require various printing techniques to introduce structural heterogeneity and functionality [112] . Finally, for effective industrial translation and commercialization of 3D printed organs, quality assurance and regulation of bioinks, bioprinters, and bioprinted products are a must. Maintaining the quality in all the steps of 3D construct regeneration can be a little more complicated. On May 10, 2016, FDA issued draft guidance regarding "Technical Considerations for Additive Manufactured Devices" that offer a clear idea to the manufacturers and all of this guidance's must be followed to get the approval from FDA. Ethical concerns can also cause problems while implanting the 3D bioprinted construct in humans [112] . Recent advancements in the 3D bioprinting discipline indicate the tremendous potential of this technique in developing functional tissues and organs for clinical transplantation [107] and developing the cardiac tissue engineering field in the innovation of relevant treatment procedures for cardiovascular diseases [120] . Analyzing the aspects of 3D bioprinting technology in cardiology more will be beneficial in solving the existing problems through practical updates [20] . Combining the high-throughput 3D bioprinting technology with stem cell technology will be a powerful concept in tissue engineering and regenerative medicine [20] . However, to generate a fully functional organ, 1-10 billion function cells are required, and the current technology is still unable to grasp the ultimate target. Thus, improving and maintaining cell density in tissue construct is still a challenge in 3D bioprinting that needs proper attention [121] . Various technologies are being integrated with 3D bioprinting technology, shifting today's 3D bioprinting technology paradigm. Integration of electronics, biosensors, and engineered tissue devices will be beneficial to create functional living cells like cardiac muscles with electrophysical signals. It will provide new tissue morphogenesis, pathogenesis, drug-responsive remodeling processes, and personalized medicine establishment [111] . Continuous chain study is needed to gain such technological advancement along with corresponding epigenetic mechanisms related to producing new cardiovascular constructs to make 3D bioprinting technology one of the most reliable, efficient, favorable methods to fabricate tissue constructs near the near future. J o u r n a l P r e -p r o o f The cases of COVID-19 infected individuals and death from this disease are increasing at an alarming rate while numerous complications are being added to the list. Myocardial injury is one of the most concerning ones now as the patients and the recovered ones face sudden heart complications, leading to death. Though conventional techniques like cardiac cell therapy and tissue engineering can replace the damaged cardiac tissues, these techniques have several drawbacks and cause various side effects, leading to death. To solve the upcoming problem, 3D bioprinting shows enormous potential as it will be helpful to generate functional, biocompatible tissue. If the damage rate is higher, it can print the whole organ and replace it with the damaged one. Studies will make this technology more appropriate to generate a heart that mimics the native nature and its features and solves the upcoming problem with accuracy. ▪ 3D bioprinting is one of the modern biotechnological developments utilized to print organs like the heart in a layer-by-layer manner on a computer-aided predetermined design. ▪ 3D bioprinting can print a heart with continuous and stable biological characteristics that mimic the native heart. ▪ Numerous case reports reveal various myocardial complications like myocardial inflammation, severe acute myocarditis, myocarditis, acute coronary syndrome, arrhythmias, heart failure, venous thromboembolism. 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein Host Factors in Coronavirus Replication Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China Supplemental content Impact of COVID-19 on the Cardiovascular System: A Review Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Chloroquine cardiomyopathy-a review of the literature Ventricular Arrhythmia Risk Based on Ethnicity in COVID-19 Patients on Hydroxychloroquine and Azithromycin Combination: Viewpoint. SN comprehensive clinical medicine, 1-6. Advance online publication COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): A randomised, double-blind, controlled phase 4 trial increases in rheumatoid arthritis: a meta-analysis of randomized controlled trials Tissue engineering therapy for cardiovascular disease Cardiac cell therapy trials: chronic myocardial infarction and congestive heart failure Advances in 3D bioprinting technology for cardiac tissue engineering and regeneration 3D bioprinted heart provides new tool for surgeons -College of Engineering at Carnegie Mellon University Clinical features of patients infected with 2019 novel co ronavirus in Wuhan Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China Clinical Characteristics of 138 Hospitalized Patients with Novel Coronavirus-Infected Pneumonia in Wuhan, China Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study Myocardial localization of coronavirus in COVID-19 cardiogenic shock COVID-19 and the cardiovascular system Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Cases From the Chinese Center for Disease Control and Prevention Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin The ACE2 expression in human ACE2 deficiency and SARS-CoV-2 infection COVID-19, ACE2, and the cardiovascular consequences Involvement of cardiovascular system as the critical point in coronavirus disease 2019 (COVID-19) prognosis and recovery. Hell Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic The biological basis for cardiac repair after myocardial infarction COVID-19 Pandemic: Cardiovascular Complications and Future Implications The Science Underlying COVID-19: Implications for the Cardiovascular System COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs Clinical review: Myocardial depression in sepsis and septic shock COVID-19 cardiac injury: Implications for long-term surveillance and outcomes in survivors Coronary microembolization and microvascular dysfunction Heart failure and COVID-19 Clinical characteristics of coronavirus disease 2019 ( COVID-19 ) in China : A systematic review and meta-analysis SARS-CoV-2, ACE2, and Hydroxychloroquine: Cardiovascular Complications, Therapeutics, and Clinical Readouts in the Current Settings. Pathogens COVID-19 and Cardiovascular Disease Cardiac Involvement in a Patient with Coronavirus Disease 2019 (COVID-19) Cardiological society of India position Clinical and immunological features of severe and moderate coronavirus disease 2019 Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered from Coronavirus Disease 2019 (COVID-19) Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19 Cardiovascular system and CoviD-19: Perspectives from a developing country Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China Cardiovascular disease and COVID-19 COVID-19 and the heart: An update for clinicians Yang Yan-zong. Clinical characteristics and mortality of patients in the intensive care unit with and without new-onset arrhythmias. Signa Vitae Cardiac and arrhythmic complications in patients with COVID-19 In the eye of the storm: the right ventricle in COVID-19 Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19 : An updated analysis Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis Incidence of thrombotic complications in critically ill ICU patients with COVID-19 COVID-19 and Age-related mortality rate: A Vicious Circle 3-D bioprinting technologies in tissue engineering and regenerative medicine: Current and future trends Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis Characterisation of a soft elastomer poly(glycerol sebacate) designed to match the mechanical properties of myocardial tissue Cellular cardiomyoplasty and cardiac tissue engineering for myocardial therapy Myocardial tissue engineering Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors Cellular cardiomyoplasty with autologous skeletal myoblasts for ischemic heart disease and heart failure Cell transplantation as future therapy for cardiovascular disease Cardiac tissue engineering: current state-of-the-art materials, cells and tissue formation In vivo tumor formation from primate embryonic stem cells Embryonic stem cell immunogenicity increases upon differentiation after transplantation into ischemic myocardium Spatial and temporal kinetics of teratoma formation from murine embryonic stem cell transplantation Plasticity of adult stem cells Skeletal myoblast transplantation in ischemic heart failure: Long-term follow-up of the first phase I cohort of patients Autologous intramyocardial injection of cultured J o u r n a l P r e -p r o o f skeletal muscle-derived stem cells in patients with non-acute myocardial infarction The basics of cell therapy to treat cardiovascular disease: One cell does not fit all Myoblast transplantation: feasibility, safety and efficacy Fundamentals of Tissue Engineering and Regenrative Medicine Recent advances and challenges on application of tissue engineering for treatment of congenital heart disease Myocardial Tissue Engineering for Regenerative Applications 3D printing approaches for cardiac tissue engineering and role of immune modulation in tissue regeneration Challenges in cardiac tissue engineering Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts Electrical stimulation systems for cardiac tissue engineering Medium perfusion enables engineering of compact and contractile cardiac tissue High-density seeding of myocyte cells for cardiac tissue engineering Electrical stimulation systems for cardiac tissue engineering Oxygen gradients correlate with cell density and cell viability in engineered cardiac tissue Current advances in 3D bioprinting technology and its applications for tissue engineering 3D bioprinting and its potential impact on cardiac failure treatment: An industry perspective 3D bioprinting-a step towards heart tissue regeneration 3D printing approaches for cardiac tissue engineering and role of immune modulation in tissue regeneration 3D bioprinting for cardiovascular regeneration and pharmacology 3D bioprinting and in vitro cardiovascular tissue modeling 3D Bioprinting for Organ Regeneration Rapid casting of patterned vascular networks for perfusable engineered three-dimensional tissues Microporous cell-laden hydrogels for engineered tissue constructs Controlling the Spatial Organization of Cells and Extracellular Matrix Proteins in Engineered Tissues Using Ultrasound Standing Wave Fields Vascularization of Three-Dimensional Collagen Hydrogels Using Ultrasound Standing Wave Fields Spatial patterning of endothelial cells and vascular network formation using ultrasound standing wave fields Ultrasound patterning technologies for studying vascular morphogenesis in 3D Bio-inks for 3D bioprinting: Recent